Category: Alimera Sciences
Here's a look at some of the top Wall Street stories for medical device companies this week: Boston Scientific could take CRM lead; Orthofix CFO bails after 6 months amid deepening financial fix; Fourth time's the charm: pSivida, Alimera jump on FDA nod for Iluvien; Echo Therapeutics is on the ropes; Activist investor erupts at Volcano
, Boston Scientific
, Echo Therapeutics Inc.
, Engaged Capital
, Food & Drug Administration (FDA)
, Leerink Swann
, Orthofix International
, pSivida Corp.
, St. Jude Medical
, Alimera Sciences
Shares of pSivida and Alimera Sciences jump after the FDA approves their Iluvien treatment for diabetic macular edema.
Georgia-based Alimera Sciences sells 6.3 million shares in a private placement funding round that raised $37.5 million.
Alimera Sciences (NSDQ:ALIM) raised $37.5 million in a recent funding round, planning on using the funds to support general corporate operations.
pSivida's shares spike 35% on news that the company's Iluvien eye drug/device combination will skip ahead to final FDA review, bypassing the advisory panel process.
The UK's National Institute for Health & Care Excellence OK's pSivida's Iluvien drug/device combo for cataract surgery patients with chronic diabetic macular edema.
pSivida (NSDQ:PSDV) said the UK's National Institute for Health & Care Excellence approved its Iluvien drug/device combination.
The approval is for cataract surgery patients who don't respond to standard treatment for diabetic macular edema, according to a press release.
Wall Street flees from pSivida and licensee Alimera Sciences as the FDA hands down its 3rd rejection for the Iluvien vision repair implant.
France grants Alimera's Iluvien vision repair implant national insurance coverage, with up to 100% reimbursement for certain patients.
The French National Health Authority granted Alimera Sciences (NSDQ:ALIM) national insurance coverage for the Iluvien vision repair implant, the company said this week.